Screening a novel FGF3 antagonist peptide with anti-tumor effects on breast cancer from a phage display library

Molecular Medicine Reports

Volumn 12, Issue 5, 2015, Pages 7051-7058

  Wang, Wei ^a   Chen, Tao ^b   Li, Haicheng ^b   Chen, Yuhui ^b   Wu, Zhilong ^a   Feng, Tongming ^a   Zhang, Xilin ^a   Zhong, Qiu ^b   Zhong, Qianhong ^a   Li, Guozhou ^c   Guo, Lina ^d   Zhou, Lin ^b   Zhou, Jie ^a  

^a the Second Hospital of Nanhai District Foshan City   (China)

^b Guangdong Institute for Food and Drug Control   (China)

^c Chronic Disease Control and Prevention Station of Dongguan ^*  (China)

^d GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

Author keywords

Breast cancer; Cell cycle; Fibroblast growth factor 3; Phage display; Proliferation

Indexed keywords

AMINO ACID; ANTINEOPLASTIC AGENT; CYCLIN D1; CYCLINE; FIBROBLAST GROWTH FACTOR 3; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PEPTIDE FP 16; PROLIFERATION ASSOCIATED PROTEIN 2G4; PROTEIN; PROTEIN KINASE B; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR RECEPTOR; PEPTIDE; PEPTIDE LIBRARY; PROTEIN BINDING; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER; CELL CYCLE G0 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ISOLATION; DRUG SCREENING; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; PHAGE DISPLAY; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SEQUENCE ANALYSIS; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BREAST TUMOR; CHEMISTRY; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PATHOLOGY; PEPTIDE LIBRARY; PHOSPHORYLATION; PRECLINICAL STUDY; SIGNAL TRANSDUCTION; SYNTHESIS; TUMOR CELL LINE;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DRUG EVALUATION, PRECLINICAL; FEMALE; FIBROBLAST GROWTH FACTOR 3; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; PEPTIDE LIBRARY; PEPTIDES; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION;

EID: 84943616841     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.4248     Document Type: Article

References (29)

1. Beenken A and Mohammadi M: The FGF family: Biology, pathophysiology and therapy. Nat Rev Drug Discov 8: 235-253, 2009.
2. Mohammadi M, Olsen SK and Ibrahimi OA: Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev 16: 107-137, 2005.
3. Rusnati M and Presta M: Fibroblast growth factors/fibroblast growth factor receptors as targets for the development of anti-angiogenesis strategies. Curr Pharm Des 13: 2025-2044, 2007.
4. Saxena R and Dwivedi A: ErbB family receptor inhibitors as therapeutic agents in breast cancer: Current status and future clinical perspective. Med Res Rev 32: 166-215, 2012.
5. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
6. Yamamoto M, Hosoda M, Nakano K, et al: p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Sci 105: 81-88, 2014.
7. Choi SY, Chang YW, Park HJ, Kim HJ, Hong SS and Seo DY: Correlation of the apparent diffusion coefficiency values on diffusion-weighted imaging with prognostic factors for breast cancer. Brit J Radiol 85: E474-E479, 2012.
8. van de Vijver MJ: Molecular tests as prognostic factors in breast cancer. Virchows Arch 464: 283-291, 2014.
9. Donegan WL: Tumor-related prognostic factors for breast cancer. CA Cancer J Clin 47: 28-51, 1997.
10. Dickson C, Spencer-Dene B, Dillon C and Fantl V: Tyrosine kinase signalling in breast cancer: Fibroblast growth factors and their receptors. Breast Cancer Res 2: 191-196, 2000.
11. Grose R and Dickson C: Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev 16: 179-186, 2005.
12. Ibrahimi OA, Zhang F, Eliseenkova AV, Itoh N, Linhardt RJ and Mohammadi M: Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet 13: 2313-2324, 2004.
13. Penault-Llorca F, Bertucci F, Adélaïde J, Parc P, Coulier F, Jacquemier J, Birnbaum D and deLapeyrière O: Expression of FGF and FGF receptor genes in human breast cancer. Int J Cancer 61: 170-176, 1995.
14. Wu XP, Huang HX, Wang C, Lin S, Huang Y, Wang Y, Liang G, Yan Q, Xiao J, Wu J, et al: Identification of a novel peptide that blocks basic fibroblast growth factor-mediated cell proliferation. Oncotarget 4: 1819-1828, 2013.
15. Fu M, Wang C, Li Z, Sakamaki T and Pestell RG: Minireview: Cyclin D1: Normal and abnormal functions. Endocrinology 145: 5439-5447, 2004.
16. Pagès G, Lenormand P, L'Allemain G, Chambard JC, Meloche S and Pouysségur J: Mitogen-activated protein kinases p42mapk and p44mapk are required for fibroblast proliferation. Proc Natl Acad Sci USA 90: 8319-8323, 1993.
17. Xia X, Cheng A, Lessor T, Zhang Y and Hamburger AW: Ebp1, an ErbB-3 binding protein, interacts with Rb and affects Rb transcriptional regulation. J Cell Physiol 187: 209-217, 2001.
18. Maga G and Hubscher U: Proliferating cell nuclear antigen (PCNA): A dancer with many partners. J Cell Sci 116: 3051-3060, 2003.
19. Zhang JT and Liu Y: Use of comparative proteomics to identify potential resistance mechanisms in cancer treatment. Cancer Treat Rev 33: 741-756, 2007.
20. Kandel E: Tumor-associated oncogenes go on (phage) display. Oncotarget 1: 84-85, 2010.
21. Ionov Y: A high throughput method for identifying personalized tumor-associated antigens. Oncotarget 1: 148-155, 2010.
22. Bae DG, Kim TD, Li G, Yoon WH and Chae CB: Anti-Flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis. Clinical Cancer Res 11: 2651-2661, 2005.
23. Yardley DA, Hart L, Bosserman L, Salleh MN, Waterhouse DM, Hagan MK, Richards P, DeSilvio ML, Mahoney JM and Nagarwala Y: Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen. Breast Cancer Res Treat 137: 457-464, 2013.
24. Knights V and Cook SJ: De-regulated FGF receptors as therapeutic targets in cancer. Pharmacol Ther 125: 105-117, 2010.
25. Li Y, Hively WP and Varmus HE: Use of MMTV-Wnt-1 transgenic mice for studying the genetic basis of breast cancer. Oncogene 19: 1002-1009, 2000.
26. Turnbull C, Ahmed S, Morrison J, et al: Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42: 504-547, 2010.
27. Roy D and Calaf GM: Allelic loss at chromosome 11q13 alters FGF3 gene expression in a human breast cancer progression model. Oncol Rep 32: 2445-2452, 2014.
28. Sherr CJ: G1 phase progression: Cycling on cue. Cell 79: 551-555, 1994.
29. Welsh CF, Roovers K, Villanueva J, Liu YQ, Schwartz MA and Assoian RK: Timing of cyclin D1 expression within G1 phase is controlled by Rho. Nat Cell Biol 3: 950-957, 2001.